32 completed, 8 terminated, 2 withdrawn, 1 not yet recruiting. 45 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 45 | Completed 32, Terminated 8, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 6 | Completed 5, Unknown 1 |
Follow secukinumab: new trials by email Literature Review of secukinumab trials Research Report on secukinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients Secukinumab, Standard of Care (SOC) - Takayasu Arteritis, Large Vessel Vasculitis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 52 | 2026-04-01 | 2026-03-27 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum secukinumab 150 mg (2 injections per dose - Pyoderma Gangrenosum | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-05-28 | |
| Personalized Therapies in Inflammatory Complex Disease Kineret, Humira, Stelara - Inflammatory Disease, Autoimmune Diseases | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 32 | 2020-10-20 | 2026-05-20 |
| PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo - Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris | Phase 2 | Completed | Novartis Pharmaceuticals | 111 | 2020-07-27 | 2023-08-22 |
| COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Colchicine, Ruxolitinib 5 MG, Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] - COVID 19 | Phase 2 | Completed | Lomonosov Moscow State University Medical Research and Educational Center | 70 | 2020-05-08 | 2022-11-25 |
| A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457） SHR-1210, AIN 457 - Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Yanqiao Zhang | 40 | 2020-03-15 | 2020-03-16 |
| A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus Secukinumab - Discoid Lupus Erythematosus | Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-09-01 | 2021-09-08 | |
| Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD) Secukinumab - Necrobiosis Lipoidica Diabeticorum | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 4 | 2019-04-03 | 2024-05-17 |
| A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Secukinumab 300 mg, s.c., Prednisolone, Placebo - Giant Cell Arteritis | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2019-01-30 | 2023-08-21 |
| Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis Secukinumab 300 mg, Placebo - Dermatitis, Atopic, Eczema, Atopic | Phase 2 | Completed | GWT-TUD GmbH | 22 | 2018-09-18 | 2021-05-03 |
| A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis M1095 (Sonelokimab), Placebo, Secukinumab - Psoriasis | Phase 2 | Completed | Bond Avillion 2 Development LP | 313 | 2018-07-31 | 2021-08-03 |
| Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy secukinumab, Placebo - Tendinopathy | Phase 2 | Completed | Novartis Pharmaceuticals | 96 | 2017-12-15 | 2021-10-08 |
| Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Secukinumab - Papulopustular Rosacea | Phase 1 / Phase 2 | Completed | Anne Chang | 24 | 2017-06-21 | 2020-02-05 |
| Safety and Efficacy of Secukinumab in Mild Psoriasis Secukinumab, Placebo followed by Secukinumab - Psoriasis | Phase 2 | Completed | James G. Krueger, MD, PhD | 23 | 2017-05-23 | 2022-10-21 |
| The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Secukinumab, Placebo - Ichthyosis, Autosomal Recessive Congenital Ichthyosis | Phase 2 | Completed | Northwestern University | 20 | 2016-12-01 | 2021-08-25 |
| Effect of Secukinumab in the Treatment of Psoriatic Arthritis Secukinumab - Psoriatic Arthritis | Phase 2 | Completed | University of Liverpool | 30 | 2016-10-15 | 2020-04-09 |
| Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Secukinumab - Pyoderma Gangrenosum | Phase 1 / Phase 2 | Completed | Technical University of Munich | 8 | 2016-04-01 | 2023-04-12 |
| Secukinumab for Treatment of Atopic Dermatitis Secukinumab, Placebo - Atopic Dermatitis | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 41 | 2015-11-01 | 2019-06-12 |
| A Study of Secukinumab for the Treatment of Alopecia Areata Secukinumab, Placebo - Alopecia Areata | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 11 | 2015-11-01 | 2021-03-11 |
Showing 20 of 45. Sign in to see all of them.
Arthritis, Rheumatoid (5) · Psoriasis (5) · Arthritis, Psoriatic (4) · Autoimmune Diseases (3) · Crohn Disease (2) · Dermatitis, Atopic (2) · Giant Cell Arteritis (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Plaque, Amyloid (2) · Polymyalgia Rheumatica (2) · Pyoderma Gangrenosum (2) · Rheumatic Diseases (2) · Skin Diseases (2) · Spondylitis, Ankylosing (2)
Novartis Pharmaceuticals (27) · Assistance Publique - Hôpitaux de Paris (2) · Icahn School of Medicine at Mount Sinai (2) · Anne Chang (1) · Beth Israel Deaconess Medical Center (1) · Bond Avillion 2 Development LP (1) · GWT-TUD GmbH (1) · James G. Krueger, MD, PhD (1) · Lomonosov Moscow State University Medical Research and Educational Center (1) · Massachusetts General Hospital (1) · NYU Langone Health (1) · Northwestern University (1) · Technical University of Munich (1) · University of Erlangen-Nürnberg Medical School (1) · University of Liverpool (1)
United States (26) · Germany (19) · United Kingdom (7) · Czechia (6) · Russia (6) · France (5) · Japan (5) · Belgium (4) · Netherlands (4) · Poland (4) · Canada (3) · Hungary (3) · Iceland (3) · Italy (3) · Bulgaria (2)
Alexa Kimball, MD MPH (1) · Amy Paller, MD (1) · Anne Chang, MD (1) · Dr. Kim Papp (1) · Emma Guttman, MD, PhD (1) · Emma Guttman-Yassky, MD, PhD (1) · Gideon Smith, MD (1) · James G Krueger, MD, PhD (1) · Jonathan Samuels, MD (1) · Kilian Eyerich, MD, PhD (1) · Mark Lebwohl, MD (1)
PMID 20926833, PMID 22595313, PMID 22730366, PMID 24035250, PMID 24393602, PMID 24429175, PMID 25638011, PMID 26248638, PMID 26268815, PMID 26834211, PMID 30053825, PMID 31349876, PMID 32907626, PMID 33894834, PMID 34404463, PMID 34658014, PMID 35218370, PMID 36197049, PMID 37505393, PMID 37794275, PMID 38251601, PMID 39400109, PMID 39988349
2009 (4), 2008 (3), 2017 (2), 2015 (1), 2016 (1), 2018 (1), 2019 (1)